spesolimab spesolimab spesolimab, sold under the brand name spevigo, is a monoclonal antibody medication used for the treatment of generalized pustular psoriasis (gpp). it is an interleukin-36 receptor (il1rl2/il1rap) antibody. spesolimabmonoclonal antibodytypewhole antibodysourcehumanizedtargetinterleukin 36 receptor (il1rl2/il1rap)clinical datatrade namesspevigoother namesbi-655130, spesolimab-sbzoahfs/drugs.commonographlicense data us dailymed: spesolimab routes ofadministrationintravenousatc codel04ac22 (who) legal statuslegal status us: ℞-only eu: rx-only identifierscas number2097104-58-8drugbankdb15626unii5ib2j79mcxkeggd12066chemical and physical dataformulac6480h9988n1736o2012s46molar mass145880.08 g·mol−1 it was approved for medical use in the united states in september 2022, and in european union in december 2022. the us food and drug administration (fda) considers it to be a first-in-class medication. society and culture legal status on 13 october 2022, the committee for medicinal products for human use (chmp) of the european medicines agency (ema) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product spevigo, intended for the treatment of flares in adult patients with generalised pustular psoriasis. the applicant for this medicinal product is boehringer ingelheim international gmbh. spesolimab was approved for medical use in the european union in december 2022.